Abstract:Hepatic stellate cells (HSC) play a central role in the pathogenesis of liver fibrosis. Following liver injury, these cells proliferate and are activated to a profibrogenic myofibroblastic phenotype. In addition to increased matrix protein synthesis, there is evidence to indicate that these cells are able to regulate matrix degradation. In the early phases of their cellular activation, HSC release matrix metalloproteinases with the ability to degrade the normal liver matrix. When HSC are fully activated, there is a net down-regulation of matrix degradation mediated by increased synthesis and extracellular release of tissue inhibitors of metalloproteinase (TIMP)-1 and -2. These studies in cell culture have been complemented by in vivo studies of hepatic TIMP-1 and TIMP-2 gene expression. In advanced human liver disease of various aetiologies, there is increased TIMP-1-mRNA and protein and increased TIMP-2-mRNA in fibrotic liver compared with control liver. Temporal studies of progressive rat liver fibrosis caused by bile duct ligation or by carbon tetrachloride, indicate an important role for increased TIMP-1 and TIMP-2 expression in pathogenesis. Moreover, in a rat model of reversible liver fibrosis, matrix remodelling and resolution of liver fibrosis is closely associated, temporally, with a marked decrease in TIMP-1 and TIMP-2 expression. These combined cell culture and in vivo findings have led us to investigate the mechanisms of regulation of TIMP-1 gene expression in hepatic stellate cells. Our recent data indicate that transcriptional regulation of TIMP-1 gene expression in HSC is mediated via a mechanism which differs considerably from that previously identified in skin fibroblasts. We conclude that increased TIMP-1 and TIMP-2 expression by HSC plays an important role in the pathogenesis of liver fibrosis. This may represent an important therapeutic target in the design of anti-fibrotic strategies for chronic liver disease.

Matrix Metallo-proteinase Inhibitor-1 and Hepatic Fibrosis

TIMP-1 in the Process of the Formation and Development of Hepatic Fibrosis Influence

Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis

Research progress of liver fibrosis and MMPs and TIMPs

Matrix metalloproteinase functions in hepatic injury and fibrosis

Tissue Inhibitor of Matrix Metalloproteinase-1 Promotes Myocardial Fibrosis by Mediating CD63–Integrin Β1 Interaction

Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis

Growth Factor Family and Hepatic Fibrosis

Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model

Matrix Mechanics as Regulatory Factors and Therapeutic Targets in Hepatic Fibrosis

Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis

Targeting Tissue Inhibitor Of Metalloproteinase 1/2 Using A Shrna Lentiviral System Offers A Novel Treatment Strategy Against Hepatic Fibrosis

Extracellular Matrix Metabolism and Fibrotic Disease

Effects of Antisense Tissue Imhibitor of Metalloproteinase-1 Expressing Plasmid on Porcine Serum-Induced Rat Liver Fibrosis

Clinical significance of tissue inhibitor of metalloproteinases-1 in livers of patients with chronic hepatitis B

Transforming Growth Factor-Β1 Induced Epithelial-Mesenchymal Transition in Hepatic Fibrosis.

Modified Synthetic Sirna Targeting Tissue Inhibitor of Metalloproteinase‐2 Inhibits Hepatic Fibrogenesis in Rats

TIMP-1 Promotes Expression of MCP-1 and Macrophage Migration by Inducing Fli-1 in Experimental Liver Fibrosis

Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis

Matrix metalloproteinases in liver injury, repair and fibrosis

The role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanisms